PHSI-BRG
Home
Staff
Theophile Bigirumurame
Andy Bryant
Thomas Chadwick
Svetlana Cherlin
Mike Cole
Holly Fisher
Tony Fouweather
Michael Grayling
Shaun Hiu
Valentina Mamasoula
John Matthews
Helen Mossop
Jérémie Nsengimana
Vicky Ryan
Dawn Teare
James Wason
Faye Williamson
Nina Wilson
Haiyan Zheng
PhD students
Ruqayya Azher
Aritra Mukherjee
Luke Ouma
Samuel Sarkodie
Lou Whitehead
Methodology research
Overview
Adaptive designs
Projects
Publications
News
Contact
Helen Mossop
Biostatistician
Population Health Sciences Institute
Contact
Email:
helen.mossop@ncl.ac.uk
Address:
Population Health Sciences Institute
,
Baddiley-Clark Building
, Richardson Road, Newcastle upon Tyne NE2 4AX, UK
Publications
You can quickly discover relevant content by members of the PHSI-BRG by filtering publications
here
.
Brief alcohol intervention for risky drinking in young people aged 14–15 years in secondary schools: The SIPS JR-HIGH RCT
Public Health Research
2019; 7(9)
Giles EL
,
McGeechan GJ
,
Coulton S
,
Deluca P
,
Drummond C
,
Howel D
,
Kaner E
,
McColl E
,
McGovern R
,
Scott S
,
Stamp E
,
Sumnall H
,
Todd L
,
Vale L
,
Albani V
,
Boniface S
,
Ferguson J
,
Gilvarry E
,
Hendrie N
,
Howe N
,
Mossop H
,
Ramsay A
,
Stanley G
,
Newbury-Birch D
DOI
Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis
Thorax
2019; 74(4):346-353
Dutta P
,
Funston W
,
Mossop H
,
Ryan V
,
Jones R
,
Forbes R
,
Sen S
,
Pearson J
,
Griffin M
,
Smith J
,
Ward C
,
Forrest I
,
Simpson J
Project
DOI
ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): Study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial
Trials
2018; 19:616
Forbes R
,
Ali A
,
Abouhajar A
,
Brennand C
,
Brown H
,
Carnell S
,
Chadwick T
,
Eardley I
,
Lecouturier J
,
Mossop H
,
Pearce I
,
Pickard R
,
Thiruchelvam N
,
Walton K
,
Wilkinson J
,
Harding C
DOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Lancet Oncology
2016; 17(8):1047-1060
Dearnaley D
,
Syndikus I
,
Mossop H
,
Khoo V
,
Birtle A
,
Bloomfield D
,
Graham J
,
Kirkbride P
,
Logue J
,
Malik Z
,
Money-Kyrle J
,
O’Sullivan JM
,
Panades M
,
Parker C
,
Patterson H
,
Scrase C
,
Staffurth J
,
Stockdale A
,
Tremlett J
,
Bidmead M
,
Mayles H
,
Naismith O
,
South C
,
Gao A
,
Cruickshank C
,
Hassan S
,
Pugh J
,
Griffin C
,
Hall E
DOI
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Lancet Oncology
2015; 16(16):1605-1616
Wilkins A
,
Mossop H
,
Syndikus I
,
Khoo V
,
Bloomfield D
,
Parker C
,
Logue J
,
Scrase C
,
Patterson H
,
Birtle A
,
Staffurth J
,
Malik Z
,
Panades M
,
Eswar C
,
Graham J
,
Russell M
,
Kirkbride P
,
O’Sullivan JM
,
Gao A
,
Cruickshank C
,
Griffin C
,
Dearnaley D
,
Hall E
DOI
DNA-repair defects and olaparib in metastatic prostate cancer
New England Journal of Medicine
2015; 373(18):1697-1708
Mateo J
,
Carreira S
,
Sandhu S
,
Miranda S
,
Mossop H
,
Perez-Lopez R
,
Nava Rodrigues D
,
Robinson D
,
Omlin A
,
Tunariu N
,
Boysen G
,
Porta N
,
Flohr P
,
Gillman A
,
Figueiredo I
,
Paulding C
,
Seed G
,
Jain S
,
Ralph C
,
Protheroe A
,
Hussain S
,
Jones R
,
Elliott T
,
McGovern U
,
Bianchini D
,
Goodall J
,
Zafeiriou Z
,
Williamson CT
,
Ferraldeschi R
,
Riisnaes R
,
Ebbs B
,
Fowler G
,
Roda D
,
Yuan W
,
Wu Y-M
,
Cao X
,
Brough R
,
Pemberton H
,
A’Hern R
,
Swain A
,
Kunju LP
,
Eeles R
,
Attard G
,
Lord CJ
,
Ashworth A
,
Rubin MA
,
Knudsen KE
,
Feng FY
,
Chinnaiyan AM
,
Hall E
,
de Bono JS
DOI
Cite
×